Physician profile
Jenna Fitzpatrick
NPI 1386192987
$8,667.79
in general payments reported to CMS, 2019-2025
34 companies · $2,255 in 2025
The $2,255 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $761 · 2022: $1,240 · 2023: $1,799 · 2024: $2,612 · 2025: $2,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,519 · Travel and Lodging: $690 · Education: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,518.63 |
| Travel and Lodging | $689.84 |
| Education | $457.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $1,109.15 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Inspire Medical Systems, INC. | $1,041.02 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $901.22 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $860.90 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $618.27 | 2021-2025 | |
| Genzyme Corporation | $483.59 | 2021-2025 | |
| Harmony Biosciences LLC | $436.67 | 2022-2025 | Wakix |
| Baxter Healthcare | $377.06 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.66 | 2022-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $285.85 | 2021-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $276.02 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $240.65 | 2022-2025 | Glassia |
| Amgen INC. | $186.67 | 2022-2025 | Tezspire |
| Pulmonx Corporation | $161.84 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $145.97 | 2023-2025 | Opsumit, Uptravi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $140.22 | 2023-2025 | Lumryz |
| Mylan Specialty L.P. | $131.37 | 2023-2024 | Yupelri |
| Axsome Therapeutics, INC. | $122.98 | 2022-2025 | Sunosi |
| Inogen, INC. | $120.19 | 2024-2025 | |
| Electromed, INC. | $84.31 | 2021-2024 | Smartvest |
| Mallinckrodt Hospital Products INC. | $82.26 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Genentech USA, INC. | $71.91 | 2021-2023 | Xolair, Esbriet |
| Grifols USA, LLC | $71.55 | 2022-2024 | Prolastin-C Liquid |
| Insmed, INC. | $68.81 | 2022-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $67.78 | 2024-2025 | Winrevair |
| Covis Pharma Gmbh | $38.06 | 2022-2023 | |
| Advanced Respiratory, INC | $20.93 | 2021 | |
| Viatris Specialty LLC | $19.71 | 2025 | Yupelri |
| Phadia US INC. | $18.86 | 2023 | Immunocap |
| Verona Pharma, INC. | $18.19 | 2025 | Ohtuvayre |
| Arbor Pharmaceuticals, INC. | $13.08 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.92 | 2023 | Quviviq |
| Pfizer INC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.